Literature DB >> 29076078

Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Assessment of Agreement Between Clinicians' Decision and CHA2DS2-VASc and HAS-BLED Scores.

Marzieh Balaghi-Inalou1, Saeed Alipour Parsa1, Latif Gachkar1, Sasan Andalib2.   

Abstract

INTRODUCTION: To prevent stroke, anticoagulants should be administered after calculation of CHA2DS2-VASc and HAS-BLED scores in patients with Atrial Fibrillation (AF); nonetheless, these scores are sometimes neglected in clinical settings. AIM: The present study was designed to assess agreement of anticoagulant therapy according to clinicians and CHA2DS2-VASc and HAS-BLED scores in Iranian AF patients in Moddares Hospital.
METHODS: AF patients were diagnosed according to clinical history, clinical examination, and electrocardiogram. Data including the anticoagulant prescription according to clinicians were recorded. CHA2DS2-VASc and HAS-BLED scores were then calculated for each patient. Agreement of anticoagulant therapy according to clinicians and CHA2DS2-VASc and HAS-BLED scores was analyzed using Cohen's kappa coefficient.
RESULTS: 97.5% of the patients (n = 117) were appropriately (according CHA2DS2-VASc and HAS-BLED scores) treated with anticoagulants by clinicians, notwithstanding a 2.5% of patients with inappropriate anticoagulant therapy (n = 3). The Cohen's kappa coefficient was 0.81 (P = 0.0).
CONCLUSIONS: The findings of the present study suggest an almost perfect agreement between anticoagulant therapy according to clinicians and that according to CHA2DS2-VASc and HAS-BLED scores in the studied population.

Entities:  

Keywords:  Agreement assessment; Atrial fibrillation; CHA2DS2-VASc; Clinician decision; HAS-BLED

Mesh:

Substances:

Year:  2017        PMID: 29076078     DOI: 10.1007/s40292-017-0237-9

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  22 in total

1.  Measures of clinical agreement for nominal and categorical data: the kappa coefficient.

Authors:  L Cyr; K Francis
Journal:  Comput Biol Med       Date:  1992-07       Impact factor: 4.589

2.  Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation.

Authors:  Deirdre A Lane; Gregory Y H Lip
Journal:  Circulation       Date:  2012-08-14       Impact factor: 29.690

3.  Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.

Authors:  Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

4.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

5.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

6.  Stroke due to atrial fibrillation and the attitude to prescribing anticoagulant prevention in Italy. A prospective study of a consecutive stroke population admitted to a comprehensive stroke unit.

Authors:  C Gandolfo; M Balestrino; A Burrone; M Del Sette; C Finocchi
Journal:  J Neurol       Date:  2008-06-20       Impact factor: 4.849

7.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.

Authors:  P A Wolf; T R Dawber; H E Thomas; W B Kannel
Journal:  Neurology       Date:  1978-10       Impact factor: 9.910

8.  Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world.

Authors:  Alexandre Meiltz; Marc Zimmermann; Philip Urban; Antoine Bloch
Journal:  Europace       Date:  2008-04-10       Impact factor: 5.214

9.  Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.

Authors:  Elena Birman-Deych; Martha J Radford; David S Nilasena; Brian F Gage
Journal:  Stroke       Date:  2006-03-09       Impact factor: 7.914

10.  Interleukin-6, a reliable prognostic factor for ischemic stroke.

Authors:  Sheyda Shaafi; Ehsan Sharifipour; Rouhollah Rahmanifar; SeyedShamseddin Hejazi; Sasan Andalib; Masoud Nikanfar; Behzad Baradarn; Robab Mehdizadeh
Journal:  Iran J Neurol       Date:  2014-04-03
View more
  3 in total

1.  Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence.

Authors:  Eyob Alemayehu Gebreyohannes; Sandra Salter; Leanne Chalmers; Luke Bereznicki; Kenneth Lee
Journal:  Am J Cardiovasc Drugs       Date:  2020-12-28       Impact factor: 3.571

2.  Atrial fibrillation: risk factors and comorbidities in a tertiary center in Jeddah, Saudi Arabia.

Authors:  Abdullah Abdulfattah Mashat; Ahmed Hussein Subki; Moaz Abdulrahman Bakhaider; Wejdan Mohammad Baabdullah; Jawaher Badr Walid; Abdulrahman Hatim Alobudi; Maged Mazen Fakeeh; Anas Jamal Algethmi; Wesam Awad Alhejily
Journal:  Int J Gen Med       Date:  2019-01-11

3.  Multimorbidity, physical frailty, and self-rated health in older patients with atrial fibrillation.

Authors:  Hawa O Abu; Jane Saczynski; Jordy Mehawej; Tenes Paul; Hamza Awad; Benita A Bamgbade; Isabelle C Pierre-Louis; Mayra Tisminetzky; Catarina I Kiefe; Robert J Goldberg; David D McManus
Journal:  BMC Geriatr       Date:  2020-09-11       Impact factor: 4.070

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.